Biomedical subjects

M Sánchez-Cabezudo

Publications and source records attributed to M Sánchez-Cabezudo.

5 recordsLinked to original sources

PubMed1996

Enzymic determinations with rotating bioreactors and continuous-flow-stopped-flow processing. Determination of choline esters in pharmaceuticals.

The neuromuscular blocking agent, succinylcholine, and the neurotransmitter, acetylcholine, have been determined in pharmaceutical preparations utilizing a sensing unit comprised of a rotating bioreactor and an amperometric detector. The bioreactor consisted of a rotating disk made of Teflon (1 cm id) with cholinesterase (EC 3.1.1.8) and choline oxidase (EC 1.1.3.17) co-immobilized on the top surface of the disk. Amperometric detection of H2O2 and initial rate measurements were employed for quantification.

Acetylcholine↗

PubMed1994

Fluorimetric determination of alkaline phosphatase activity in human serum by use of a flow-through biosensor.

A fluorimetric method for the determination of alkaline phosphatase activity based on the use of a flow-through biosensor is reported. The biochemical basis of the method is the hydrolysis of 4-methyl-umbelliferone-phosphate catalyzed by the analyte with fluorimetric monitoring of the 4-methyl-umbelliferone formed (lambda ex = 365 nm, lambda em = 445 nm). The enhancement of sensitivity achieved when the reaction product is retained on the support packed in the flow-cell makes the method suitable for determination of the analytes in serum samples after 1:50 dilution. The linear range is found to be between 0.1 and 20 U l-1, with relative standard deviation less than 2.2%. The use of this biosensor was tested by the determination of the analyte in human serum from healthy and sick individuals with excellent recoveries (94-103%).

Alkaline Phosphatase↗

PubMed1994

Relation of abnormal composition of lipoproteins to HbA1c levels in non-insulin dependent diabetes.

Plasma lipids and VLDL and HDL composition were studied in a control group of 20 non diabetic subjects and in 31 male middle-age patients with non-insulin dependent diabetes treated by oral hypoglycemic agent glibenclamide and a weight maintaining diet. Data for the diabetics were separated based on haemoglobin A1c of less or greater than 7%. VLDL composition abnormalities were more frequent in the diabetic patients with HbA1c of > 7%. VLDL-cholesterol, VLDL-triglycerides and VLDL-phospholipids were high in all diabetics whereas VLDL-apo B increased only in diabetics with HbA1c > 7%. Apo CII and apo CIII levels and also apo CII/apo CIII ratio were also reduced in the diabetic patients with HbA1c levels of more than 7%. Increases in the apo E and apo E/apo C ratio were also seen in the more hyperglycemic diabetics with HbA1c levels > 7%. In contrast apo CII and apo CIII levels and also Apo CII/Apo CIII ratio remained unaltered in diabetic patients with less than 7% HbA1c levels. In these patients increases in the apo E levels were found while the apo E/apo C ratio remained unaltered. All diabetic patients showed increases in HDL-triglycerides and triglyceride/total cholesterol ratio with respect to control. Decreases in HDL-apo AI were also seen in both groups of diabetics, but the HDL-apo AI/HDL-apo AII ratio did not differ from control.

Apolipoproteins↗

PubMed1993

Plasma lipids and VLDL composition in male non-insulin dependent diabetic patients: relation with HbA1c levels.

In this study, plasma lipids and VLDL composition were measured in 22 middle aged male patients with non-insulin dependent diabetes and compared with 15 non-diabetic controls. Data for the diabetics were differentiated on the basis of hemoglobin A1c levels of less than or greater than 7%. Compositional abnormalities of VLDL were more frequent in the diabetic patients with HbA1c of > 7%. VLDL-cholesterol, triglycerides and phospholipids were elevated in all diabetics whereas VLDL-Apo B was increased only in diabetics with HbA1c > 7%. Apo CII and Apo CIII levels and also apo CII/apo CIII ratio were also reduced with HbA1c levels of more than 7%. Increases in the apo E and apo E/apo C ratio were also seen in the more hyperglycemic diabetics with HbA1c levels of > 7%. In contrast apo CII and apo CIII levels and also apo CII/apo CIII ratio remained unaltered in diabetic patients with less than 7% HbA1c levels. In these patients increases in the apo E levels were found while the apo E/apo C ratio remained unaltered.

Administration, Oral↗

PubMed1993

[Correlations of the levels of HbA1c with plasma apoproteins and plasma lipoproteins in type II diabetic patients].

Plasma apolipoproteins from VLDL, LDL and HDL lipoproteins were measured in 56 male patients with age range 50-60 years and noninsulin-dependent diabetes mellitus (type II) and 81 normal volunteers. Diabetic patients were further divided into two subgroups according to the HbA1c (glycated haemoglobin) concentrations, lower than 7% and higher than 7% respectively, after considering that HbA1c levels may be an appropriate index to monitor long-term blood glucose level. The studied groups, control and diabetic patients, were well matched with regard to age, % of smokers, % drinkers and % hypertensive and physical activity. The relationships between glucose, fructosamine and % HbA1c levels were investigated. In addition, the relationships between glucose, fructosamine, HbA1c levels and apolipoproteins from the lipoproteins were also studied. A significant correlation (p < 0.05) between glucose/fructosamine, glucose/HbA1c and fructosamine/HbA1c was found in both groups of diabetic patients with HbA1c lower than 7% and higher than 7% respectively. However HbA1c levels were positive and significantly (p < 0.05) correlated with the Apo-B and Apo-E and negative but significantly correlated (p < 0.05) with Apo-CII and Apo-CIII from VLDL particle in both groups of diabetic patients.

Apolipoproteins↗